CMS Revises No Surprises Act Dispute Resolution Process: Operational, Reimbursement, and Strategic Implications for Providers, Health Plans, and Investors

Healthcare providers, physician groups, hospitals, health plans, insurers, staffing companies, investors, and private equity-backed healthcare platforms should prepare for operational, reimbursement, revenue cycle, and dispute-resolution changes as federal regulators attempt to streamline a No Surprises Act dispute resolution system that has processed millions of payment disputes and become a critical component of out-of-network reimbursement.

The Departments of Health and Human Services (“HHS”), Labor, and Treasury, together with the Office of Personnel Management (“OPM”), recently issued the Federal Independent Dispute Resolution Operations Final Rule, making significant changes to the Federal Independent Dispute Resolution (“IDR”) process established under the No Surprises Act. Although the No Surprises Act is most commonly associated with protecting patients from unexpected out-of-network medical bills, the Federal IDR process has evolved into one of the most important reimbursement mechanisms for resolving payment disputes between healthcare providers and health plans, insurers, and other payors involving emergency services, certain facility-based services, and air ambulance transportation.

Since implementation of the No Surprises Act in 2022, dispute volumes have significantly exceeded federal projections, with federal regulators reporting more than 5.1 million disputes submitted for review as of January 31, 2026. The Federal IDR process has become particularly important for healthcare organizations operating in specialties that frequently encounter out-of-network reimbursement disputes, including emergency medicine, anesthesiology, radiology, pathology, and air ambulance services. The Final Rule reflects the federal government’s latest effort to stabilize and improve a dispute resolution system that has faced litigation, temporary portal shutdowns, administrative backlogs, eligibility disputes, and ongoing disagreement regarding reimbursement obligations and payment methodologies.

Why the Rule Matters

The Final Rule does not fundamentally alter the patient protections established by the No Surprises Act or rewrite the core arbitration framework used to resolve reimbursement disputes. Instead, federal regulators are attempting to address operational challenges that have complicated administration of the Federal IDR process since its inception. In doing so, regulators are targeting recurring issues that have contributed to delays, administrative inefficiencies, eligibility disputes, communication failures, and growing frustration among providers, payors, and certified IDR entities responsible for administering the process.

Among other changes, the Final Rule establishes new communication requirements for payors, modifies open negotiation procedures, revises batching rules, accelerates eligibility determinations, creates a new Federal IDR Registry, and reduces the administrative fees associated with participation in the Federal IDR process. One of the most significant changes involves reducing the administrative fee from $115 per party per dispute to $15 per party per dispute, a move that may improve access to the Federal IDR process for organizations managing significant volumes of reimbursement disputes. The rule also seeks to reduce the number of disputes that ultimately prove ineligible for arbitration by requiring earlier information sharing, creating more structured negotiation procedures, and establishing faster eligibility review timelines.

Implications for Providers and Physician Groups

Healthcare providers and physician groups that routinely utilize the Federal IDR process should evaluate how the new requirements may affect existing revenue cycle operations, reimbursement strategies, dispute-resolution procedures, and administrative workflows. The Final Rule imposes additional procedural requirements during the open negotiation phase, requires greater information exchange between disputing parties before arbitration begins, and establishes accelerated timelines for determining whether disputes qualify for Federal IDR review. The revised batching provisions may also provide additional opportunities for providers to consolidate qualifying disputes, potentially reducing administrative burden and dispute-related costs.

The operational impact may be particularly significant for emergency medicine groups, anesthesiology practices, radiology groups, pathology providers, air ambulance providers, physician staffing companies, and hospital-based physician organizations that rely heavily upon the Federal IDR process as part of their reimbursement strategy. Organizations utilizing outside billing vendors, revenue cycle consultants, or reimbursement counsel may also wish to review existing procedures to ensure that operational workflows remain aligned with the revised regulatory requirements.

Implications for Health Plans and Insurers

Payors face several new operational and compliance obligations under the Final Rule. Among other requirements, plans and issuers must provide additional identifying information when issuing initial payments or notices of denial and must utilize specified claim adjustment and remittance codes intended to improve transparency regarding whether claims may be subject to the No Surprises Act and eligible for the Federal IDR process. The rule also establishes a new Federal IDR Registry requiring registration by participating plans and insurers, which regulators believe will improve communication, assist eligibility determinations, reduce administrative confusion, and support future enforcement efforts.

These changes may require modifications to existing claims administration, reimbursement review, compliance, and dispute-management processes. Organizations involved in high volumes of out-of-network claims should carefully assess how the new requirements may affect operational efficiency, dispute handling, and overall reimbursement strategy.

Implications for Investors and Healthcare Transactions

Investors and private equity-backed healthcare platforms should not view the Final Rule solely as a reimbursement development. For many provider organizations, reimbursement obtained through the Federal IDR process represents a meaningful revenue source that can influence financial performance, valuation assumptions, revenue cycle performance, and long-term business planning. Changes affecting dispute costs, eligibility determinations, processing efficiency, batching strategy, and reimbursement workflows therefore have the potential to affect much more than claims administration.

Healthcare organizations evaluating acquisitions, platform expansions, physician practice transactions, management arrangements, joint ventures, or other strategic transactions involving specialties with significant out-of-network reimbursement exposure may wish to assess historical IDR activity, reimbursement trends, dispute outcomes, operational infrastructure, and dependence upon Federal IDR recoveries. The continuing evolution of the Federal IDR process through agency guidance, rulemaking, and ongoing litigation may remain an important consideration when evaluating reimbursement risk and long-term investment strategy.

Effective Dates and Implementation Considerations

The Final Rule generally becomes effective 60 days after publication in the Federal Register. However, not all provisions become applicable at the same time. Most notably, the reduced administrative fee of $15 per party per dispute will apply to disputes initiated on or after five business days following publication of the Final Rule, while certain batching provisions will apply to disputes with open negotiation periods beginning 90 days after the rule’s effective date.

Several operational changes, including portions of the revised Federal IDR process and the new Federal IDR Registry, will not become applicable until after the Departments issue future guidance announcing that the necessary Federal IDR portal functionality is available. Accordingly, healthcare organizations, payors, and revenue cycle teams should begin evaluating operational and compliance workflows now while recognizing that implementation of key provisions will occur in phases.

Key Takeaway

The larger issue may no longer be whether the Federal IDR process exists. The federal government is now attempting to stabilize and operationalize a dispute resolution system that has become a critical component of out-of-network reimbursement for many healthcare providers, health plans, insurers, and other payors. Organizations that routinely utilize the Federal IDR process should evaluate dispute-resolution strategies, revenue cycle workflows, reimbursement assumptions, compliance procedures, vendor relationships, and operational readiness before the new requirements become applicable.

As the No Surprises Act continues to evolve through rulemaking, agency guidance, portal updates, and litigation, healthcare organizations, physician groups, hospitals, staffing companies, payors, and investors should continue monitoring developments that may further affect reimbursement practices and dispute-resolution strategies throughout the healthcare industry.